The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence

Journal of Experimental & Clinical Cancer Research

Xun-bo Jin¹  Guan-bin Li¹  Yong Zhao¹  Qing-hua Xia¹  Shao-bo Jiang¹  Zi-lian Cui¹  Hui Xiong¹  Yu-zhu Xiang¹ 

[1] Minimally Invasive Urology Center, Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China

关键词: Aggressiveness;    Clinical stage;    Recurrence;    Gleason score;   

Others  :  825411
DOI  :  10.1186/1756-9966-32-9

 received in 2013-01-13, accepted in 2013-02-08,  发布年份 2013

【 摘 要 】

Background

Although a previous meta-analysis reported no association between metabolic syndrome (MetS) and prostate cancer risk, a number of studies suggest that MetS may be associated with the aggressiveness and progression of prostate cancer. However, these results have been inconsistent. This systematic review and meta-analysis investigated the nature of this association.

Methods

We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to January 2013 using the keywords “metabolic syndrome” and “prostate cancer”. We assessed relative risks (RRs) of the prostate cancer, several parameters of prostate cancer aggressiveness and progression associated with MetS using 95% confidence intervals (95% CIs).

Results

The literature search produced 547 hits from which 19 papers were extracted for the meta-analysis. In cancer-free population with and without MetS, the combined adjusted RR (95% CI) of prostate cancer risk and prostate cancer-specific mortality in longitudinal cohort studies is 0.96 (0.85 ~ 1.09) and 1.12 (1.02 ~ 1.23) respectively. In the prostate cancer patients with and without MetS, the combined unadjusted OR (95% CI) of high grade Gleason prostate cancer is 1.44 (1.20 ~ 1.72), the OR of advanced prostate cancer is 1.37 (1.12 ~ 1.68) and the OR of biochemical recurrence is 2.06 (1.43 ~ 2.96).

Conclusions

The overall analyses revealed no association between MetS and prostate cancer risk, although men with MetS appear more likely to have high-grade prostate cancer and more advanced disease, were at greater risk of progression after radical prostatectomy and were more likely to suffer prostate cancer-specific death. Further primary studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are required.

【 授权许可】

   
2013 Xiang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
• [3]Nelson WG, De Marzo AM, Isaacs WB: Prostate cancer. N Engl J Med 2003, 349(4):366-381.
• [4]Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
• [5]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
• [6]Pothiwala P, Jain SK, Yaturu S: Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009, 7(4):279-288.
• [7]Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, La Vecchia C: Metabolic syndrome and endometrial cancer risk. Ann Oncol 2011, 22(4):884-889.
• [8]Pelucchi C, Negri E, Talamini R, Levi F, Giacosa A, Crispo A, Bidoli E, Montella M, Franceschi S, La Vecchia C: Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 2010, 46(10):1866-1872.
• [9]Rosato V, Tavani A, Bosetti C, Pelucchi C, Talamini R, Polesel J, Serraino D, Negri E, La Vecchia C: Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism 2011, 60(10):1372-1378.
• [10]Zhou JR, Blackburn GL, Walker WA: Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr 2007, 86(3):s817-s819.
• [11]Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT: Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004, 13(10):1646-1650.
• [12]Tande AJ, Platz EA, Folsom AR: The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006, 164(11):1094-1102.
• [13]Russo A, Autelitano M, Bisanti L: Metabolic syndrome and cancer risk. Eur J Cancer 2008, 44(2):293-297.
• [14]Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI: Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009, 20(7):1181-1192.
• [15]Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S: Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 2009, 18(3):240-247.
• [16]Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B: The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomarkers Prev 2010, 19(8):2088-2096.
• [17]Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV: The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: Results from the Olmsted County Study. BJU Int 2011, 107(6):929-935.
• [18]Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T: Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol 2012, 36(2):141-147.
• [19]Haggstrom C, Stocks T, Ulmert D, Bjorge T, Ulmer H, Hallmans G, Manjer J, Engeland A, Nagel G, Almqvist M, et al.: Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012, 118(24):6199-6206.
• [20]Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA: Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009, 74(1):185-190.
• [21]Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C: The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011, 21(11):835-841.
• [22]Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D: Metabolic Syndrome and Risk of Cancer: A systematic review and meta-analysis. Diabetes Care 2012, 35(11):2402-2411.
• [23]Castillejos-Molina R, Rodriguez-Covarrubias F, Sotomayor M, Gomez-Alvarado MO, Villalobos-Gollas M, Gabilondo F, Feria-Bernal G: Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Urol Int 2011, 87(3):270-275.
• [24]Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh QD, Pokala N, Sharma P, Menon M, Agarwal PK: Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol 2012. Epub ahead of print
• [25]De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, Tubaro A: Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011. Epub ahead of print
• [26]Morote J, Ropero J, Planas J, Bastaros JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventos J, et al.: Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2012. Epub ahead of print
• [27]Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, Rundle A, Jankowski M, Rybicki BA: The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy. Prostate Cancer 2011, 2011:245642.
• [28]Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS: Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Korean J Urol 2012, 53(9):593-597.
• [29]B.K H: The characteristics of prostate cancer with metabolic syndrome in Korean men. Korean J Urol 2007, 48(6):585-591.
• [30]Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN: Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer 2009, 45(10):1831-1838.
• [31]Antonio C, Francesco C, Cosimo DN, Andrea T, Rocco D: Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: a prospective single cohort study. Urol Oncol 2012. Epub ahead of print
• [32]Hammarsten J, Hogstedt B: Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005, 41(18):2887-2895.
• [33]Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA: Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 2012. Epub ahead of print
• [34]Lund Haheim L, Wisloff TF, Holme I, Nafstad P: Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006, 164(8):769-774.
• [35]Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA: Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 2007, 109(5):875-881.
• [36]Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
• [37]Hsing AW, Sakoda LC, Chua S Jr: Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007, 86(3):s843-857.
• [38]Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, Qiu J, Lei H: Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 2012. Epub ahead of print
• [39]Li L, Yang Y, Yang G, Lu C, Yang M, Liu H, Zong H: The role of JAZF1 on lipid metabolism and related genes in vitro. Metabolism 2011, 60(4):523-530.
• [40]Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL: Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001, 11(8):534-542.
• [41]Ganesh B, Saoba SL, Sarade MN, Pinjari SV: Risk factors for prostate cancer: An hospital-based case-control study from Mumbai, India. Indian J Urol 2011, 27(3):345-350.
• [42]Martin RM, Vatten L, Gunnell D, Romundstad P: Blood pressure and risk of prostate cancer: Cohort Norway (CONOR). Cancer Causes Control 2010, 21(3):463-472.
• [43]Discacciati A, Orsini N, Wolk A: Body mass index and incidence of localized and advanced prostate cancer–a dose-response meta-analysis of prospective studies. Ann Oncol 2012, 23(7):1665-1671.
• [44]Siegel R, Naishadham D, Jemal A: CA Cancer J Clin. 2012, 62(1):10-29.
• [45]Jung HS, Myung SK, Kim BS, Seo HG: Metabolic syndrome in adult cancer survivors: a meta-analysis. Diabetes Res Clin Pract 2012, 95(2):275-282.